Facial beauty is very important for personal image. Facial burns, bruises, scars, and surgeries can all lead to facial scarring, which not only affects the aesthetic appearance but also has an impact on facial and jaw function. With the increasing importance of beauty in modern society, particularly for female patients, the demand for scar treatment that also meets aesthetic needs is growing.
Traditional methods, such as skin flap grafting, can improve patient function, but cannot fully satisfy their aesthetic requirements. With the continuous development of the medical beauty industry, laser treatment has been found to not only effectively improve facial scarring but also has good aesthetics, meeting patient demands for aesthetic results. However, longer wound healing time after surgery increases the risk of infection. To solve this problem, this article mainly analyzes the application of recombinant human epidermal growth factor in accelerating wound healing during laser scar repair.
Recombinant human epidermal growth factor is widely distributed in the body fluids and tissues of humans, and can accelerate cell division and proliferation, thereby speeding up tissue repair. It can stimulate the growth of endothelial cells, keratinocytes, and smooth muscle cells, while promoting the expression of extracellular matrix such as hyaluronic acid, proteoglycan, and fibronectin, thus improving local microcirculation to provide a good environment for epidermal cell growth and reducing metabolite accumulation. Recombinant human epidermal growth factor is an exogenous epidermal growth factor, which has high structural and activity similarity to natural epidermal factors, and has been proven to accelerate epithelial cell regeneration in various clinical studies, thus shortening wound healing time.
Some researchers have pointed out that recombinant human epidermal growth factor can increase the expression level of hydroxyproline, thus accelerating collagen synthesis and promoting epidermal cell regeneration. In the study observation, the wound healing rate and granulation tissue maturity grade of the observation group after 1 and 2 weeks were higher than those of the control group (P＜0.05), indicating that external application of recombinant human epidermal growth factor can accelerate wound healing and granulation tissue maturation, thus shortening the healing time for patients. At the same time, no adverse reactions occurred in either group, indicating that the use of recombinant human epidermal growth factor has high safety.
Overall, recombinant human epidermal growth factor has high efficacy and safety in facial scar repair.
